CagriSema is being investigated by Novo Nordisk as a once-weekly subcutaneous injectable treatment for adults with overweight or obesity (REDEFINE programme) and as a treatment for adults with type 2 diabetes (REIMAGINE programme).
CagriSema is an investigational product that combines the GLP-1 RA, semaglutide, with an amylin analog, cagrilintide.
Also Read: Novo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe’s Largest Company
REDEFINE 1 Trial
If all patients adhered to treatment, CagriSema resulted in a greater weight loss of 22.7% at 68 weeks versus 2.3% in the placebo group.
When evaluating the treatment effect regardless of adherence, those treated with CagriSema achieved a statistically significant weight loss of 20.4% at 68 weeks versus 3.0% for the placebo group.
In addition, a supportive secondary analysis showed that half (50.7%) of trial participants with obesity treated with CagriSema reached the threshold for non-obesity (BMI < 30 kg/m2) at the end of treatment, from a mean BMI of 38 kg/m2 at the start of treatment.
In the placebo group,10.2% reached that threshold at 68 weeks.
Select confirmatory secondary endpoints showed that if all participants adhered to treatment, 40.4% of those receiving CagriSema achieved a weight reduction of ≥25%.
Additionally, 23.1% lost ≥30% of their ...
